Archives of Gynecology and Obstetrics

, Volume 278, Issue 1, pp 1–12 | Cite as

Depot-medroxyprogesterone acetate: an update

  • Sayed Bakry
  • Zaher O. Merhi
  • Trudy J. Scalise
  • Mohamad S. Mahmoud
  • Ahmed Fadiel
  • Frederick Naftolin
Review Article



Depo-Provera® is a contraceptive approved by the US Food and Drug Administration (FDA) since 1992 and used worldwide by more than 90 million women.

Aim of study

Despite the fact that progestins are endogenous hormones that are secreted by the body, its excess might lead to detrimental health effects. Whether progestins as contraceptives are friends or foes is a questionable matter. In this manuscript, we drive the attention to both usage and side effects Depo-Provera.


Depot-medroxyprogesterone acetate (DMPA) is a highly effective, convenient non-daily hormonal contraceptive option that has been available worldwide for many years. The experience with DMPA provides a large body of long-term data regarding the efficacy and safety of this contraceptive method; this long-term experience has established that the use of DMPA does not increase the risk of cardiovascular events, breast cancer, other gynecologic malignancy, or postmenopausal fracture; however, patients are often more concerned about the relatively immediate effects of contraceptives such as potential changes in menstrual cycle, body weight, and mood disturbances.


Concerns about such issues may lead to reluctance to initiate therapy or premature discontinuation. Counseling and understanding of women’s concerns and experiences using Depo-Provera is important and could help health care providers redesign counseling strategies to improve contraceptive continuation and improve patient adherence.


Depo-Provera Risk of cardiovascular events Osteoporosis Gynecologic malignancy Body weight gain 


  1. 1.
    Camaggi CM, Strocchi E, Giovannini M (1983) Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administrations in advanced cancer patients. Cancer Chemother Pharmacol 11:19–22PubMedCrossRefGoogle Scholar
  2. 2.
    Wright CE, Antal EJ, Gillespie WR (1983) Effect of injection volume on the bioavailability of sterile Medroxyprogesterone acetate suspension. Clin Pharm 2:435–438PubMedGoogle Scholar
  3. 3.
    Blossey HC, Bartsch HH, Kanne D (1982) The pharmacokinetics of high-dose Medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer. Cancer Chemother Pharmacol 8:77–81PubMedCrossRefGoogle Scholar
  4. 4.
    Speroff L, Glass RH, Kase NG (1989) Clinical gynecologic endocrinology and infertility. 4th ed. Williams & Wilkins, Baltimore, MDGoogle Scholar
  5. 5.
    Goodman-Gilman A, Rall TW, Nies AS (1990) Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. Pergamon, New York, NY, pp 1397–1401Google Scholar
  6. 6.
    Hatcher RA, Stewart F, Trussell J (1990) Contraceptive technology 1990–1992. 15th ed. Irvington, New York, NYGoogle Scholar
  7. 7.
    Speroff L, Darney PD (1992) A clinical guide for contraception. Williams & Wilkins, Baltimore, MDGoogle Scholar
  8. 8.
    Product Information (1998) Depo-Provera(R), medroxyprogesterone. The Upjohn Company, Kalamazoo, MIGoogle Scholar
  9. 9.
    Product Information (1999) Premphase (R), conjugated estrogens/medroxyprogesterone acetate. Wyeth Ayerst Laboratories, Philadelphia, PAGoogle Scholar
  10. 10.
    Di Celser K, Gruber C, Hayes C (1982) Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 2:229–232Google Scholar
  11. 11.
    Notelovitz M, Kitchens G, Ware M (1983) Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 62:596–600PubMedGoogle Scholar
  12. 12.
    Roche J (1984) Steroid-induced arachnoiditis. Med J Aust 140:281–284PubMedGoogle Scholar
  13. 13.
    Kirkham C, Hahn PM, Van Vugt DA (1991) A randomized, double-blind, placebo-controlled, cross-over trial to asses the side effect of medroxyprogesterone acetate in hormone replacement therapy. Obstet Gynecol 78:93–97PubMedGoogle Scholar
  14. 14.
    Guiloff E, Ibarra-Polo A, Zanartu J (1974) Effect of contraception on lactation. Am J Obstet Gynecol 118:42–45PubMedGoogle Scholar
  15. 15.
    Halderman LD, Nelson AL (2002) Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am J Obstet Gynecol 186:1250–1256PubMedCrossRefGoogle Scholar
  16. 16.
    Amatayakul K, Sivasomboon B, Thanangkul O (1980) A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 22:605–622PubMedCrossRefGoogle Scholar
  17. 17.
    Moore LL, Valuck R, McDougall C, Fink W (1995) A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52:215–219PubMedCrossRefGoogle Scholar
  18. 18.
    Bahamondes L, Diaz J, Petta C, Hall P (1998) Weight variation in users of the once-a-month injectable contraceptive cyclofem. Adv Contracept 14:223–230CrossRefGoogle Scholar
  19. 19.
    Kaunitz AM (1999) Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 170:1543–1549Google Scholar
  20. 20.
    Risser WL, Gefter LR, Barratt MS, Risser JM (1999) Weight change in adolescents who used hormonal contraception. Adolesc Health 24:433–436CrossRefGoogle Scholar
  21. 21.
    Espey E, Steinhart J, Ogburn T, Qualls C (2000) Depo-Provera associated with weight gain in Navajo women. Contraception 62:55–58PubMedCrossRefGoogle Scholar
  22. 22.
    Bahamondes L, Del-Castillo S, Tabares G, Arce XE, Perrotti M, Petta C (2001) Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception 64:223–225PubMedCrossRefGoogle Scholar
  23. 23.
    Mangan SA, Larsen PG, Hudson S (2002) Overweight teens at increased risk for weight gain while using depot medroxyprogesteroneacetate. J Pediatr Adolesc Gynecol 15:79–82PubMedCrossRefGoogle Scholar
  24. 24.
    Shadoan MK, Anthony MS, Rankin SE, Clarkson TB, Wagner JD (2003) Effects of tibolone and conjugated equine estrogens with or without medroxyprogesterone acetate on body composition and fasting carbohydrate measures in surgically postmenopausal monkeys. Metabolism 52:1085–1089PubMedCrossRefGoogle Scholar
  25. 25.
    Mia AR, Siddiqui NI, Khan MR, Shampa SS, Rukunuzzaman, Akhter M, Kamrunnaher (2004) Effect of prolonged use of injectable hormonal contraceptives on blood pressure and body weight. Mymensingh Med J 13:30–32PubMedGoogle Scholar
  26. 26.
    Goldsmith NF, Johnston JO (1975) Bone mineral: effects of oral contraceptives, pregnancy, and lactation. J Bone Joint Surg Am 57:657–668PubMedGoogle Scholar
  27. 27.
    Cundy T, Cornish J, Roberts H, Elder H, Reid IR (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92:569–573PubMedCrossRefGoogle Scholar
  28. 28.
    Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR (1998) The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49:615–618CrossRefGoogle Scholar
  29. 29.
    Scholes D, LaCroix AZ, Ott SM, Ichikawa LE, Barlow WE (1999) Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 93:233–238PubMedCrossRefGoogle Scholar
  30. 30.
    Tong OS, Tang G, Yip PS, Li B (2000) Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception 62:161–164CrossRefGoogle Scholar
  31. 31.
    Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK (1996) Stroke in users of low-dose oral contraceptives. N Engl J Med 335:8–15PubMedCrossRefGoogle Scholar
  32. 32.
    Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A (2001) Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103:899–906Google Scholar
  33. 33.
    Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM (2002) Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13:581–587PubMedCrossRefGoogle Scholar
  34. 34.
    Busen NH, Britt RB, Rianon N (2003) Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health 32:257–259PubMedCrossRefGoogle Scholar
  35. 35.
    Lara-Torre E, Edwards CP, Perlman S, Hertweck SP (2004) Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 17:17–21PubMedCrossRefGoogle Scholar
  36. 36.
    Liu JH, Muse KN (2005) The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 192:1316–1323PubMedCrossRefGoogle Scholar
  37. 37.
    Kaunitz AM (1996) Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 41:419–427PubMedGoogle Scholar
  38. 38.
    Valente PT, Schantz HD, Trabal JF (1998) Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate. Cancer 25:328–334CrossRefGoogle Scholar
  39. 39.
    Jordan A (1994) Toxicology of depot medroxyprogesterone acetate. Contraception 49:189–201PubMedCrossRefGoogle Scholar
  40. 40.
    Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T et al (2007) Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25:2798–2803PubMedCrossRefGoogle Scholar
  41. 41.
    Brent RL (2005) Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 73:906–918PubMedCrossRefGoogle Scholar
  42. 42.
    Eel-Gindi E, Ahmed-Nasr M (1993) Hormonal versus genetic factors in limb and heart anomalies. Cardiovasc Surg 1:381–383Google Scholar
  43. 43.
    Wilkins L (1960) Masculinization of female fetus due to use of orally given progestins. JAMA 172:1028–1032Google Scholar
  44. 44.
    Gal I (1967) Hormonal pregnancy tests and congenital malformation. Nature 216:83PubMedCrossRefGoogle Scholar
  45. 45.
    Aarskog D )1970) Clinical and cytogenetic studies in hypospadias. Acta Paediatr Scand (suppl 203):1–62Google Scholar
  46. 46.
    Heinonen OP (1977) Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med 296:67–70PubMedGoogle Scholar
  47. 47.
    Roberts IF, West RJ (1977) Teratogenesis and maternal progesterone. Lancet II:982CrossRefGoogle Scholar
  48. 48.
    Evans ANW (1980) The ingestion by pregnant women of substances toxic to the foetus. Practitioner 224:315–319PubMedGoogle Scholar
  49. 49.
    Mann JR (1983) Transplacental carcinogenesis (adrenocortical carcinoma) associated with hydroxyprogesterone hexanoate. Lancet II:580CrossRefGoogle Scholar
  50. 50.
    Ambani LM, Joshi NJ, Vaidya RA, Devi PK (1977) Are hormonal contraceptives teratogenic? Fertil Steril 28:791–797PubMedGoogle Scholar
  51. 51.
    Bracken MB, Holford TR, White C, Kelsey JL (1978) Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 7:309–317PubMedCrossRefGoogle Scholar
  52. 52.
    Saksena SK, Salmonsen R, Lau IF (1979) Termination of pregnancy in the rat by RMI 12,936. Contraception 19:481–488PubMedCrossRefGoogle Scholar
  53. 53.
    Lau IF, Hoogasian J, Wong SK, Saksena SK (1980) Effects of prostaglandin F2 alpha and an antiprogestational steroid, RMI 12,936, on rat pregnancy. Prostaglandins Med 4:121–132PubMedCrossRefGoogle Scholar
  54. 54.
    Nora JJ, Nora AH, Blu J, Ingram J, Fountain A, Peterson M, Lortscher RH, Kimberling WJ (1980) Exogenous progestogen and estrogen implicated in birth defects. IARC Sci Publ, pp 169–178Google Scholar
  55. 55.
    Savolainen E, Saksela E, Saxen L (1981) Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 1:521–524Google Scholar
  56. 56.
    Starkov MV, Shashkina LF, Remezova MI (1975) A morphohistochemical study of the embryotropic action of steroids with androgenic properties. Arkh Patol 37:45–50PubMedGoogle Scholar
  57. 57.
    Rands PL, White RD, Carter MW, Allen SD, Bradshaw WS (1982) Indicators of developmental toxicity following prenatal administration of hormonally active compounds in the rat. I. Gestational length. Teratology 25:37–43PubMedCrossRefGoogle Scholar
  58. 58.
    Eibs HG, Spielmann H, Hagele M (1982a) Teratogenic effects of progestin treatment during the pre- and postimplantation period of mouse embryos. Teratology 22:288–289Google Scholar
  59. 59.
    Eibs HG, Spielmann H, Jacob-Muller U, Klose J (1982b) Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. II. Cyproterone acetate and medroxyprogesterone acetate treatment before implantation in vivo and in vitro. Teratology 25:291–299PubMedCrossRefGoogle Scholar
  60. 60.
    Kricker A, Elliott JW, Forrest JM, McCredie J (1986) Congenital limb reduction deformities and use of oral contraceptives. Am J Obstet Gynecol 155:1072–1078PubMedGoogle Scholar
  61. 61.
    Yovich JL, Turner SR, Draper R (1988) Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 38:135–144PubMedCrossRefGoogle Scholar
  62. 62.
    Yovich JL, Turner SR, Draper R (1989) Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Obstet Gynecol Surv 44:447–449Google Scholar
  63. 63.
    Pardthaisong T, Yenchit C, Gray R (1992) The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 45:313–324PubMedCrossRefGoogle Scholar
  64. 64.
    Anon (1982) Pregnancy categories for prescription drugs. FDA Drug Bull 12:24–25Google Scholar
  65. 65.
    Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, Mortier GR, Rimoin DL, Lachman RS, Gaines ES et al (1995) Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 10:330–336PubMedCrossRefGoogle Scholar
  66. 66.
    Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill MS (2002) Pregnancies diagnosed during Depo-Provera use. Contraception 66:169–172PubMedCrossRefGoogle Scholar
  67. 67.
    Wooltorton E (2005) Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. J Ayub Med Coll Abbottabad 172:746Google Scholar
  68. 68.
    FDA (2005) Depo-Provera (medroxyprogesterone acetate injectable suspension) revised product monograph, Pfizer. Available: (click on: November 2004—Label—Pfizer) (Accessed 8 Feb 2005)
  69. 69.
    Sannes E, Lyngset A, Nafstad I (1983) Teratogenicity and embryotoxicity of orally administered lynestrenol in rabbits. Arch Toxicol 52:23–33PubMedCrossRefGoogle Scholar
  70. 70.
    Barlow SM, Knight AF, Sullivan FM (1980) Diazepam-induced cleft palate in the mouse: the role of endogenous maternal corticosterone. Teratology 21:149–155PubMedCrossRefGoogle Scholar
  71. 71.
    Prahalada S, Hendrickx AG (1983) Embryotoxicity of Norlestrin, a combined synthetic oral contraceptive, in rhesus macaques (Macaca mulatta). Teratology 27:215–222PubMedCrossRefGoogle Scholar
  72. 72.
    Tarara R (1984) The effect of medroxyprogesterone acetate (Depo-Provera) on prenatal development in the baboon (Papio anubis): a preliminary study. Teratology 30:181–185PubMedCrossRefGoogle Scholar
  73. 73.
    Prahalada S, Carroad E, Cukierski M, Hendrickx AG (1985) Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis). Teratology 32:421–432PubMedCrossRefGoogle Scholar
  74. 74.
    Poggel A, Hendrickx AG, Korte R, Leuschner F, Neumann BW, Prahalada S, Binkerd PE, Gunzel P (1987) Embryotoxicity of sex steroidal hormone combinations in nonhuman primates: I. Norethisterone acetate + ethinylestradiol and progesterone + estradiol benzoate (Macaca mulatta, Macaca fascicularis, and Papio cynocephalus). Teratology 35:119–127PubMedCrossRefGoogle Scholar
  75. 75.
    Carbone JP, Figurska K, Buck S, Brent RL (1990) Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate. Teratology 42:121–130PubMedCrossRefGoogle Scholar
  76. 76.
    Carbone JP, Brent RL (1993) Genital and non genital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Am J Obstet Gynecol 169:1292–1298PubMedGoogle Scholar
  77. 77.
    Jordan A (1994) Toxicology of depot medroxyprogesterone acetate. Contraception 49:189–201PubMedCrossRefGoogle Scholar
  78. 78.
    Bishun N, Mills J, Parke JV, Williams DC (1975) A cytogenetic study in women who had used oral contraceptives and in their progeny. Mutat Res 33:299–310PubMedGoogle Scholar
  79. 79.
    Klinger HP, Glasser M, Kava HW (1976) Contraceptives and the conceptus. I. Chromosome abnormalities of the fetus and neonate related to maternal contraceptive history. Obstet Gynecol 48:40–48PubMedGoogle Scholar
  80. 80.
    Muller R, Ritter C (1978) Cytogenetic studies on women during and following the use of hormonal contraceptives. Zentralbl Gynakol 51:125–129Google Scholar
  81. 81.
    Tu ZH, Wang MY, Qi XD, Xu WB, Xu DH (1992) Lack of mutagenicity and teratogenicity of 16-methylene–17-alpha-acetoxy-19-norprogesterone. Zhongguo Yao Li Xue Bao 13:183–186PubMedGoogle Scholar
  82. 82.
    Shyama SK, Abdul Rahiman M (1993) Progestin (norethisterone)-induced genetic damage in mouse bone marrow. Mutat Res 300:215–221PubMedCrossRefGoogle Scholar
  83. 83.
    Herzog R, Leuschner J, Henning (1995) Evaluation of the mutagenicity of medroxyprogesterone acetate in vitro and in vivo. Arzneimittelforschung 45:311–314PubMedGoogle Scholar
  84. 84.
    Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA (2001) Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61:293–302PubMedGoogle Scholar
  85. 85.
    Giovanni B, Martelli A (2002) Are some progestins genotoxic liver carcinogens? Mutation Research 512:155–163CrossRefGoogle Scholar
  86. 86.
    Kremer J, de Bruijn HW, Hindriks FR (1980) Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate. Contraception 22:359–367PubMedCrossRefGoogle Scholar
  87. 87.
    Crona N, Enk L, Friberg LG, Samsioe G, Silfverstolpe G (1983) Changes in apolipoprotein AI after treatment with high-dose medroxyprogesterone acetate. Gynecol Obstet Invest 18:16–20CrossRefGoogle Scholar
  88. 88.
    Gronroos M, Lehtonen A (1983) Effect of high dose progestin on serum lipids. Atherosclerosis 47:101–105PubMedCrossRefGoogle Scholar
  89. 89.
    Liew DF, Ng CS, Yong YM, Ratnam SS (1985) Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31:51–64PubMedCrossRefGoogle Scholar
  90. 90.
    Enk L, Crona N, Friberg LG, Samsioe G, Silfverstolpe G (1985) High-dose depot-medroxyprogesterone acetate—effects on the fatty acid composition of serum lecithin and cholesterol ester. Gynecol Oncol 22:317–323PubMedCrossRefGoogle Scholar
  91. 91.
    Fahraeus L, Sydsjo A, Wallentin L (1986) Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 45:503–506PubMedGoogle Scholar
  92. 92.
    Wallace EM, Wu FCW (1990) Effect of medroxyprogesterone acetate and testosterone oenanthate on serum lipoproteins in man. Contraception 41:63–71PubMedCrossRefGoogle Scholar
  93. 93.
    Garza-Flores J, De la Cruz DL, Valles de Bourges V, Sanchez-Nuncio R, Martinez M, Fuziwara JL, Perez-Palacios G (1991) Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 44:61–71PubMedCrossRefGoogle Scholar
  94. 94.
    Enk L, Landgren BM, Lindberg UB, Silfverstolpe G, Crona N (1992) A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 24:85–89PubMedCrossRefGoogle Scholar
  95. 95.
    Kongsayreepong R, Chutivongse S, George P, Joyce S, McCone JM, Garza-Flores J, Valles de Bourges V, Cruz DL, Perez-Palacios G, Rosseneu M (1993) A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. Contraception 47:177–191PubMedCrossRefGoogle Scholar
  96. 96.
    Miller BG, Moore NW (1983) Endometrial protein secretion during early pregnancy in entire and ovariectomized ewes. J Reprod Fertil 68:137–144PubMedCrossRefGoogle Scholar
  97. 97.
    Canto de Cetina TE, Luna MO, Cetina Canto JA, Bassol S (2004) Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception 69:115–119CrossRefGoogle Scholar
  98. 98.
    Topcuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topcuoglu D (2005) The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 205:79–86PubMedCrossRefGoogle Scholar
  99. 99.
    Bursch W, Taper HS, Lauer B, Schulte-Hermann R (1985) Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchows Arch B Cell Pathol Incl Mol Pathol 50:153–166PubMedCrossRefGoogle Scholar
  100. 100.
    Tucker MJ, Kalinowski AE, Orton TC (1996) Carcinogenicity of cyproterone acetate in the mouse. Carcinogenesis,l 17:1473–1476CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sayed Bakry
    • 1
    • 2
  • Zaher O. Merhi
    • 3
  • Trudy J. Scalise
    • 2
  • Mohamad S. Mahmoud
    • 4
  • Ahmed Fadiel
    • 5
  • Frederick Naftolin
    • 2
  1. 1.Center for Genetic Engineering and Embryo CultureAl Azhar UniversityCairoEgypt
  2. 2.Department of Obstetrics, Gynecology and Reproductive Biology, School of MedicineNew York UniversityNew YorkUSA
  3. 3.Department of Obstetrics and GynecologyMaimonides Medical CenterBrooklynUSA
  4. 4.Department of Obstetrics and GynecologyUniversity of IllinoisIllinoisUSA
  5. 5.Yale University School of MedicineNew HavenUSA

Personalised recommendations